TY - JOUR AU - Duparc, Stephan AU - Chalon, Stephan AU - Miller, Scott AU - Richardson, Naomi AU - Toovey, Stephen PY - 2020 DA - 2020/03/14 TI - Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review JO - Malaria Journal SP - 111 VL - 19 IS - 1 AB - Tafenoquine is an 8-aminoquinoline anti-malarial drug recently approved as a single-dose (300 mg) therapy for Plasmodium vivax relapse prevention, when co-administered with 3-days of chloroquine or other blood schizonticide. Tafenoquine 200 mg weekly after a loading dose is also approved as travellers’ prophylaxis. The development of tafenoquine has been conducted over many years, using various dosing regimens in diverse populations. SN - 1475-2875 UR - https://doi.org/10.1186/s12936-020-03184-x DO - 10.1186/s12936-020-03184-x ID - Duparc2020 ER -